Stella01wilson

1
Diabetes Drug Delivery Devices Market is
projected to be worth USD 31 billion by 2030,
growing at a CAGR of 9, claims Roots
Analysis The anticipated growth in global
diabetic patient population is likely to result
in a significant rise in demand for novel, safe
and more patient friendly drug delivery
solutions for diabetics who are required to
medicate on a frequent basis Roots Analysis has
announced the addition of Diabetes Drug Delivery
Devices Market, 2020-2030 report to its list of
offerings. Stakeholders engaged in this domain
are presently focusing on introducing advanced
features, such as integrated continuous glucose
monitoring (CGM) systems, artificial
intelligence (AI) enabled algorithms, provisions
for audiovisual / tactile feedback, and
automatic drug reconstitution features. Such
efforts are primarily directed towards
differentiating proprietary offerings within a
highlight competitive market landscape, and are
expected to drive the markets growth over the
coming years. Key Market Insights More than 80
diabetes drug delivery devices are presently
available / under development More than 65 of
the aforementioned devices are marketed, while
the rest are being evaluated in preclinical /
clinical studies. It is also worth highlighting
that majority of the drug delivery devices
intended for diabetics are insulin pumps (35),
followed by pen injectors / autoinjectors
(32). Over 50 companies, across the world, claim
to be engaged in developing drug delivery
devices for diabetics Majority (44) of the
device developers are located in North America,
primarily in the US. Within Europe, most of the
developers are distributed across France,
Germany, Switzerland, Italy and UK. Further,
around 37 of the players engaged in this domain
are large firms. The market is dominated by the
products of big pharma players The leading
pharmaceutical companies (in terms of number of
products and revenues shares) involved in this
domain are large / very large businesses. It is
worth mentioning that the aforementioned players
are investing significantly in terms of number of
marketed and clinical-stage drugs, partnerships
and strategic investments in this
domain. Partnership activity in this domain has
grown at a CAGR of 33, between 2015 and 2019
2

• Maximum number of partnerships were reported in
  2018. Majority of the agreements captured in the
  report, were observed to be related to technology
  integration deals (over 35), followed by
  product development (16).
• North America and Europe are anticipated to
  capture over 60 of the overall market share by
  2030
• The current market is driven by the sales of
  diabetes drug delivery devices designed for
  subcutaneous administration (over 70), followed
  by those that facilitate intravenous
  administration (26). Further, pen injectors /
  autoinjectors currently capture 52 of the
  overall market share (in terms of sales
  revenues).
• Get Latest Market Insights https//www.rootsanaly
  sis.com/reports/diabetes- drug-delivery-devices-m
  arket/request-customization.html
• Key Questions Answered
• Who are the leading players engaged in the
  development of diabetes drug delivery devices?
• What are the popular devices types that are
  available / under development for the delivery
  of diabetes medicine?
• What kind of novel / advanced features are device
  developers incorporating into their proprietary
  offerings in order to maintain a competitive edge
  in the market?
• What kind of partnership models are commonly
  being adopted by stakeholders in this industry?
• What is the role of big pharma companies in this
  market?
• What are the factors that are likely to influence
  the evolution of this market?
• How is the current and future market opportunity
  likely to be distributed across key market
  segments?
• The USD 31 million (by 2030) financial
  opportunity within the diabetes drug delivery
  devices market has been analyzed across the
  following segments
• Type of Device
• Pen-Injectors
• Insulin Pumps
• Conventional Syringes
• Others
• Route of Administration

3

• Key Geographies
• North America
• Europe
• Asia Pacific
• Rest of the World
• The research covers detailed profiles of key
  players (listed below) each profile features an
  overview of the company, financial information
  (if available), details related to its
  technology portfolio, product portfolio, recent
  developments, and an informed future outlook.
• Bigfoot Biomedical
• Debiotech
• Haselmeier
• Medtronic
• Novo Nordisk
• Roche
• SOOIL
• Ypsomed
• Request for Customization https//www.rootsanalys
  is.com/reports/diabetes- drug-delivery-devices-ma
  rket/request-sample.html
• About Roots Analysis
• Roots Analysis is one of the fastest growing
  market research companies, sharing fresh and
  independent perspectives in the
  bio-pharmaceutical industry. The in-depth
  research, analysis and insights are driven by an
  experienced leadership team which has gained many
  years of significant experience in this sector.
  If youd like help with your growing business
  needs, get in touch at info_at_rootsanalysis.com
• Contact Information
• Roots Analysis Private Limited Gaurav Chaudhary